How many biotech companies actually reach an exit? And what sets apart the ones that get acquired or deliver returns to their investors? On 25 November at 4:00 pm, Catalonia.health and Capital Cell, a Catalonia.health member, bring together investors and entrepreneurs to discuss funding, valuation and strategy, and to learn from companies that have made it.

A panel of leading professionals from the biotech ecosystem will share first-hand experience, including two members of our board: Jordi Martorell (Aortyx), First Vice President of Catalonia.health, and Mariona Serra (GoodGut-Hipra), Second Vice President. The panel is completed by Alfons Hidalgo, business angel, and Luis Pareras (Invivo Partners), a Catalonia.health member. Startup pitches and networking follow.

Programme

• Expert panel on biotech exits

• Startup pitches from companies seeking funding (to be announced soon)

• Coffee & Networking with founders, investors and industry professionals

Who it is for

Investors, biotech founders and entrepreneurs, and ecosystem professionals who want to understand which decisions make the difference on the path to an exit.

Registration

Places are limited. Reserve your spot.

Enquiries

For any questions, write to us at Communications.